Breaking News
Get 60% Off 0
Cyber Monday Deal: Up to 60% off InvestingPro
CLAIM SALE
Close

Leap Therapeutics Inc (LPTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Leap Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.9800 +0.0600    +2.05%
29/11 - Closed. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 212,197
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 2.9000 - 3.1750
Leap Therapeutics 2.9800 +0.0600 +2.05%

Leap Therapeutics Inc Company Profile

 
Get an in-depth profile of Leap Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

54

Equity Type

ORD

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Contact Information

Address 47 Thorndike Street Suite B1-1
Cambridge, 02141
United States
Phone 617 714 0360
Fax -

Top Executives

Name Age Since Title
Douglas E. Onsi 52 2011 CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Christopher K. Mirabelli 67 2011 Chairman
James H. Cavanaugh 84 2016 Independent Director
Thomas John Dietz 57 2016 Lead Independent Director
Joseph Loscalzo 70 2016 Independent Director
William W. Li 58 2017 Independent Director
Carl F. Nathan - - Member of Scientific Advisory Board
David Tuveson - - Member of Scientific Advisory Board
Nissim Mashiach 60 2017 Independent Director
Andrew B Nixon - 2021 Member of Scientific Advisory Board
Richard B. Gaynor 73 2021 Member of Scientific Advisory Board
Eileen M. O’Reilly - 2022 Member of Scientific Advisory Board
Richard L. Schilsky 73 2022 Independent Director
Scott Joseph Antonia - 2023 Member of Scientific Advisory Board
Christian M. Richard 54 2023 Independent Director
Bernard M. Fine - 2024 Member of Scientific Advisory Board
Patricia A. Martin 63 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LPTX Comments

Write your thoughts about Leap Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email